Incretin‐based therapies not only show an increase of HOMA‐β and fasting C‐Peptide level, but also achieve a reduction of HOMA‐IR and FPG in comparison with placebo. Even though GRADE evidences indicate low to moderate for most comparisons, incretin‐based therapies seem to be advisable option for long term treatment to obtain preservation of β‐cell function (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: incretin
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti‐hyperglycaemic drugs, when added to metformin
Real world evidence in people with Type 2 diabetes (Diabetic Medicine)
Sodium-Glucose Cotransporter-2 Inhibition Improves Incretin Sensitivity of Pancreatic β-cells in Patients with Type 2 Diabetes
Dapagliflozin improved β-cell responses to incretin hormones as well as glucose during the hyperglycemic clamp in patients with inadequately controlled T2DM (Diabetes, Obesity and Metabolism)
Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis
Incretin-based treatment in patients with T1DM may improve glycemic control and reduce insulin dose and weight without increasing the risk of serious adverse event, such as severe hypoglycemia, ketosis or ketoacidosis (Diabetes Research and Clinical Practice)
Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect
Prediabetes was highly prevalent in women with pGDM, and alterations in the incretin effect were detected in this group before the development of type 2 diabetes (diabetologia)
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
In this large population-based study, use of incretin-based drugs was not associated with an increased risk of acute pancreatitis compared with other oral antidiabetic drugs (JAMA Internal Medicine)
Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus
The use of GLP-1 analogues was associated with an increased ri sk of bile duct and gallbladder disease. Physicians should be aware of this potential adverse event when prescribing these drugs (JAMA Internal Medicine)
The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure
Owing to the well-documented microvascular benefit of improved glycemic control, the identification of cardiovascular-safe diabetes drugs that effectively lower glucose remains an important clinical need. The incretin therapies thus fulfill this goal. Ultimately, we need diabetes drugs that also reduce cardiovascular risk, and that will only be demonstrated through a continued commitment to long-term outcome studies (JAMA Cardiology)
Impact of Metformin on Metastases in Patients with Breast Cancer and Type 2 Diabetes
The use of metformin and incretins in women with T2DM and BC may reduce the risk of metastases (Journal of Diabetes and Its Complications)
A Multicenter Observational Study of Incretin-based Drugs and Heart Failure
In this analysis of data from large cohorts of patients with diabetes, incretin-based drugs were not associated with an increased risk of hospitalization for heart failure, as compared with commonly used combinations of oral antidiabetic drugs (NEJM)
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
The present review will summarize the relationship between multiple adverse biological mechanisms in diabetes and putative incretin-based therapeutic interventions intended to prevent diabetic vascular complications (Journal of Diabetes Research)
Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to insulin degludec/liraglutide
Although the effects differ with each individual class of therapy, clinical trials have shown that adding a glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor or sodium-glucose co-transporter-2 inhibitor to insulin regimens can offer a significant reduction in HbA1c without substantially increasing hypoglycaemia risk, or weight (Diabetic Medicine)
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition (Diabetes, Obesity and Metabolism)
Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study
The incretin group experienced significant reduction in depressive symptoms compared to controls. This was independent of HbA1c and may be mediated by an anti-inflammatory mechanism (Primary Care Diabetes)
Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young
The pathophysiology of HNF1A-diabetes includes exaggerated postprandial glucagon responses and increased fasting DPP-4 enzymatic activity, but normal postprandial incretin responses in both patients with GCK-diabetes and HNF1A-diabetes (European Journal of Endocrinology)
Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study
Our findings suggest that the use of incretin-based drugs appears not to be associated with an increased risk of acute pancreatitis (Diabetes Care)
Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients
Disordered early phase insulin and glucagon secretions but not incretin secretion are involved in hyperglycemia after ingestion of nutrients in T2DM of even a short duration (Journal of Diabetes and Its Complications)
Glycosmedia is also available as an App: